Awakn Life Sciences (TSE:AWKN) has released an update.
Awakn Life Sciences Corp., a clinical-stage biotechnology company, has announced the successful closure of a second tranche in its private placement, raising additional funds of $394,285 through the issuance of 857,142 units. This capital boost is aimed at enhancing the company’s general working capital while advancing its focus on developing treatments for Alcohol Use Disorder. Each unit in the placement includes one common share and a purchase warrant, which potentially increases investment value for the holders.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.
